{"id":{"repo_id":"cape-town","oai_identifier":"oai:open.uct.ac.za:11427/6091"},"canonical_url":"https://search.dev.ndltd.org/etd/cape-town/oai:open.uct.ac.za:11427/6091","repository":{"repo_id":"cape-town","name":"University of Cape Town","base_url":"https://open.uct.ac.za/oai/request"},"display":{"title":"The genetics of lithium-induced adverse drug reactions in bipolar disorder patients : a pilot study","abstract":"Lithium is regarded as the first-line pharmacotherapy for the treatment of acute mood episodes, suicide prevention and prophylactic treatment in patients with bipolar disorder (BPD). Response to lithium has a strong genetic component and lithium-responders have an increased frequency of BPD among their family members. Lithium has a narrow therapeutic index and 75-90% of patients on long-term lithium treatment experience one or more side effects, such as weight gain, cognitive decline and skin problems, amongst at least 20 side effects. The research project is immersed in a larger project on the genetics of bipolar disorder, in which a large number of individuals in families have been investigated over several years. The present pilot study explored whether single nucleotide polymorphisms (SNPs) within GSK3B, AKT1, ARRB2, GRIA2 and PPPARGC1A could be associated with the incidence and severity of lithium-induced side effects.","abstract_html":"Lithium is regarded as the first-line pharmacotherapy for the treatment of acute mood episodes, suicide prevention and prophylactic treatment in patients with bipolar disorder (BPD). Response to lithium has a strong genetic component and lithium-responders have an increased frequency of BPD among their family members. Lithium has a narrow therapeutic index and 75-90% of patients on long-term lithium treatment experience one or more side effects, such as weight gain, cognitive decline and skin problems, amongst at least 20 side effects. The research project is immersed in a larger project on the genetics of bipolar disorder, in which a large number of individuals in families have been investigated over several years. The present pilot study explored whether single nucleotide polymorphisms (SNPs) within GSK3B, AKT1, ARRB2, GRIA2 and PPPARGC1A could be associated with the incidence and severity of lithium-induced side effects.","abstract_has_math":false,"creators":["Weideman, Reinette"],"institution":"Division of Human Genetics","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Ramesar, Raj","Horn, Neil"],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-07-22T22:22:55Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11427/6091","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Ramesar, Raj","Horn, Neil"]},{"key":"dc:creator","label":"Author","values":["Weideman, Reinette"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-08-13T13:51:51Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-08-13T13:51:51Z"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Division of Human Genetics"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Cape Town"]},{"key":"dc:type","label":"Dc Type","values":["Master Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Masters"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MSc"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11427/6091"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Includes abstract.","Includes bibliographical references.","Name of degree provided by the Faculty of Health Sciences."]},{"key":"dc:description.abstract","label":"Abstract","values":["Lithium is regarded as the first-line pharmacotherapy for the treatment of acute mood episodes, suicide prevention and prophylactic treatment in patients with bipolar disorder (BPD). Response to lithium has a strong genetic component and lithium-responders have an increased frequency of BPD among their family members. Lithium has a narrow therapeutic index and 75-90% of patients on long-term lithium treatment experience one or more side effects, such as weight gain, cognitive decline and skin problems, amongst at least 20 side effects. The research project is immersed in a larger project on the genetics of bipolar disorder, in which a large number of individuals in families have been investigated over several years. The present pilot study explored whether single nucleotide polymorphisms (SNPs) within GSK3B, AKT1, ARRB2, GRIA2 and PPPARGC1A could be associated with the incidence and severity of lithium-induced side effects."]},{"key":"dc:title","label":"Title","values":["The genetics of lithium-induced adverse drug reactions in bipolar disorder patients : a pilot study"]}]}],"canonical_facts":{"dc:contributor.advisor":["Ramesar, Raj","Horn, Neil"],"dc:creator":["Weideman, Reinette"],"dc:date.accessioned":["2014-08-13T13:51:51Z"],"dc:date.available":["2014-08-13T13:51:51Z"],"dc:date.issued":["2013"],"dc:description":["Includes abstract.","Includes bibliographical references.","Name of degree provided by the Faculty of Health Sciences."],"dc:description.abstract":["Lithium is regarded as the first-line pharmacotherapy for the treatment of acute mood episodes, suicide prevention and prophylactic treatment in patients with bipolar disorder (BPD). Response to lithium has a strong genetic component and lithium-responders have an increased frequency of BPD among their family members. Lithium has a narrow therapeutic index and 75-90% of patients on long-term lithium treatment experience one or more side effects, such as weight gain, cognitive decline and skin problems, amongst at least 20 side effects. The research project is immersed in a larger project on the genetics of bipolar disorder, in which a large number of individuals in families have been investigated over several years. The present pilot study explored whether single nucleotide polymorphisms (SNPs) within GSK3B, AKT1, ARRB2, GRIA2 and PPPARGC1A could be associated with the incidence and severity of lithium-induced side effects."],"dc:identifier.uri":["http://hdl.handle.net/11427/6091"],"dc:language.iso":["eng"],"dc:publisher.department":["Division of Human Genetics"],"dc:publisher.institution":["University of Cape Town"],"dc:title":["The genetics of lithium-induced adverse drug reactions in bipolar disorder patients : a pilot study"],"dc:type":["Master Thesis"],"dc:type.qualificationlevel":["Masters"],"dc:type.qualificationname":["MSc"]},"updated_at":"2026-07-22T22:22:55Z"}